RxDoctor Payments DataLook up a doctor →

Blane Mire, MD

Internal Medicine · Natchez, MSNPI 1326082397

Payments from drug & device makers

$8,406in general payments, 2019–2025

Across 525 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$992
  • Johnson & Johnson$744
  • Boehringer Ingelheim$698
  • Lilly USA, LLC$690
  • AbbVie$683
  • Merck$555
  • plus $4K from 27 others

What the payments were for

  • Food & beverage$8,30699%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,406 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$710,233
Medicare patients
1,129
Services billed
47,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$105,296
MounjaroTirzepatide85$91,595
JardianceEmpagliflozin55$48,240
TrulicityDulaglutide18$18,749
Tresiba Flextouch U-200Insulin Degludec28$18,315
JanuviaSitagliptin Phosphate27$17,214
XareltoRivaroxaban17$16,226
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$15,319
Soliqua 100-33Insulin Glargine/Lixisenatide16$14,021
EliquisApixaban24$13,767
FarxigaDapagliflozin Propanediol17$12,028
NamzaricMemantine Hcl/Donepezil Hcl14$7,465
Valsartan176$5,255
Rosuvastatin Calcium317$4,202
Atorvastatin Calcium401$2,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$690$110,345103 claims
Novo NordiskOzempic$513$105,29675 claims
Boehringer IngelheimJardiance$698$48,24055 claims
MerckJanuvia$555$17,21427 claims
Johnson & JohnsonXarelto$744$16,22617 claims
GSKTrelegy Ellipta$379$15,31914 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$405$14,02116 claims
PfizerEliquis$992$13,76724 claims
AstraZenecaFarxiga$482$12,02817 claims
AbbVieNamzaric$683$7,46514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Natchez

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →